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Introduction
The bone marrow examination is an essential
investigation for the diagnosis and management of
many disorders of  the blood and bone marrow. The
aspirate and trephine biopsy specimens are comple-
mentary and when both are obtained, they provide a
comprehensive evaluation of  the bone marrow. The
final interpretation requires the integration of
peripheral blood, bone marrow aspirate and trephine
biopsy  findings, together with the results of
supplementary tests such as, immunophenotyping,
cytogenetic analysis and molecular genetic studies as
appropriate, in the context of clinical and other
diagnostic findings. It is recommended that both BM
aspirate and biopsy be routinely performed so that
respective findings can be correlated. However, in some
clinical situations, a BM aspirate alone may suffice.
History of  bone marrow examination
The first bone marrow biopsy was reported in 1905
by Pianese. It was performed in an infant with leish-
maniasis. In 1909, Pianese trephined the tibia and fe-
mur, aspirating the marrow with a needle attached to
a syringe. In 1923, Seyfarth used a surgical trephine to
obtain marrow from the ribs and the sternum.
Because trephination resulted in excessive bleeding and
infection, it was not a generally well-accepted proce-
dure. Airinkin, in 1927, eliminated the trephine com-
plications by using a short lumbar needle to puncture
the manubrium and sternum. He obtained a marrow
aspiration by placing a syringe on the needle hub. In
1945, Vandenberghe and Blitstein were the first to use
the iliac crest to obtain bone marrow and Heidenreich
obtained marrow from the spinous processes. In 1952,
Bierman used the posterior iliac crest as the site for
bone marrow aspiration, claiming it to be a safe site.
Indications for bone marrow examination
1. Investigation of  unexplained anaemia, abnormal
red cell indices, cytopenias or cytoses.
2. Investigation of  abnormal peripheral blood smear
morphology, suggestive of  bone marrow pathol-
ogy.
3. Diagnosis, staging and follow-up of malignant
haematological disorders (e.g. acute and chronic
leukaemias, myelodysplastic syndromes, chronic
myeloproliferative disorders, lymphomas, plasma
cell myeloma, amyloidosis, mastocytosis).
4. Investigation of suspected bone marrow me-
tastases.
5. Unexplained focal bony lesions on radiological
imaging.
6. Unexplained organomegaly or presence of mass
lesions inaccessible for biopsy.
7. Microbiological culture for investigations of pyr-
exia of  unknown origin or specific infections, e.g.
miliary tuberculosis, leishmaniasis, malaria.
8. Evaluation of  iron stores.
9. Investigation of  lipid/glycogen storage disorders.
10. Exclusion of haematological disease in potential
allogeneic stem cell transplant donors.
Contraindication
Hemophilia and other related disorders.
Preparations prior to the procedure
1. The procedure should be explained in detail to
the patient. The past clinical history of the patient
should be obtained, any allergies and co-morbidi-
ties documented and any premedications explained.
2. Informed consent should be obtained from the
patient. Consent should also be obtained, accord-
ing to local guidelines, for the use of any speci-
mens for non-diagnostic purposes, e.g. research,
tissue banking, education or quality assurance.
3. A blood count and smear should be obtained if
these have not been collected in the previous 2
days.
4. Adequate sedation and analgesia determined
5. Assessment of thrombocytopenia or
coagulopathic risks, which may require platelet
transfusion support or the reversal of anticoagu-
lation.
6. Consider site for BM examination carefully.
Choosing a site
The preferred anatomic site for BM aspiration and
trephine biopsy is the posterior iliac crest. The ante-
rior iliac crest can be used if the patient is immobile.
The medial surface of the tibia can also be used in
infants. A sternal aspirate may be appropriate in cer-
tain circumstances, e.g. if  the patient is immobile, has
received radiotherapy to the pelvis or other sites have
yielded a ‘dry tap’ or if a trephine biopsy is not re-
quired. Sternal aspiration should only be performed
by an experienced operator who is aware of the risk
of cardiac tamponade. Sternal aspiration should not
be attempted in patients with suspected plasma cell
myeloma or other disorders associated with bone re-
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sorption. If there is a known focal bone lesion (from
radiological imaging), diagnostic information may be
obtained if a needle aspirate and bone biopsy is also
performed at the site.
The procedure
It is recommended that the aspirate and trephine bi-
opsy be obtained using the respective needles sepa-
rately, and not through a trephine needle. If  the aspi-
rate is performed with a trephine needle, the aspirate
sample may be haemodiluted. If the biopsy is then
performed using the same needle, the trephine core
may be damaged or haemorrhagic.
The procedure – Bone marrow aspiration
1. Special attention to positioning of the patient
should be given to immobile patients, obese pa-
tients, paediatric patients or infants, patients with
lytic bone lesions or BM necrosis, or those who
have had prior radiotherapy. The prior prepara-
tions should be ensured.
2. The second and third fingers on the hand not be-
ing used to insert the needle should be placed on
the iliac crest or spine and the needle inserted be-
tween them. The needle and stylet are pushed into
the bone with a slight rotary motion. When it is
felt that the needle is firmly in place, the stylet is
removed and a 10- or 20-ml plastic syringe is at-
tached. The patient is then told that he/she may
feel an unpleasant sensation, and the plunger of
the syringe is pulled back vigorously with no more
than 0.5 ml of bone marrow and blood aspi-
rated
3. The 10- or 20-ml plastic syringe, attached to the
aspiration needle provides adequate negative pres-
sure.
4. Bone marrow smears should be prepared imme-
diately following aspiration and a report given.
The procedure – Bone marrow biopsy
The BM trephine biopsy may be performed either
before or after the aspirate. The length of the core
from an adult should be at least 2 cm.
A small incision with a scalpel blade is made before
insertion of the biopsy needle and stylet. A different
site should be chosen for the biopsy, if  it is performed
after the aspiration. After insertion of the biopsy needle
into the bone, the stylet is removed. The needle is then
advanced between 1 and 2 cm, depending on the size
of  the patient. This is performed with very little rota-
tion of the needle. After advancing the needle, the hub
is rotated a few times in one direction, followed by a
few times in the other direction. The needle is inserted
a small additional amount to break the attachment,
and the rotations are repeated. The thumb is then
placed on the hub of the needle, and the needle is
extracted with slight lateral movements accompany-
ing the removal. The bone marrow biopsy is then
placed on a slide, where imprints are made before
processing for cytologic investigations.
After decalcification, the biopsy specimen is embed-
ded in paraffin wax and sections cut on a microtome.
The recommended thickness of sections is two to three
microns. At least six sections should be cut at three
levels: 25%, 50%, and 75% into the cross-sectional
diameter of the core, and serial sections mounted
stepwise on glass slides. Additional sections need to
be cut if IHC or histochemical stains are required.
Complications
Rarely mortality may follow this procedure. A needle
may break; bleeding may follow especially in thromb-
ocytopenic patients. Infections may be introduced and
rarely pulmonary thromboembolism may complicate
the procedure.
Interpretation of results
A hematology consult is very useful in interpreting re-
sults where the clinical picture and all blood and bone
marrow results are reviewed to reach a diagnosis.
The recommended bone aspirate report
Name of institution.
Unique specimen identifier (laboratory accession num-
ber).
Details of patient: surname, first name(s), identifica-
tion number, age or date of birth, gender, contact
details (e.g. address, hospital location).
Name of responsible physician.
Name of  requesting doctor.
Date of procedure.
Significant clinical history including physical findings,
recent chemo/radiotherapy, cytokine therapy and per-
tinent lab results.
Indication for bone marrow examination.
Procedure performed (aspirate/trephine biopsy).
Anatomic site of  aspirate/biopsy.
Ease/difficulty of aspiration.
Blood count: Haemoglobin concentration, total and
differential white cell count (neutrophils, eosinophils,
basophils, monocytes, lymphocytes) and platelet count.
Blood smear description and diagnostic conclusion.
Cellularity of  particles and cell trails.
Nucleated differential cell count.






                                                   Annals of Ibadan Postgraduate Medicine. Vol.8 No.1 June, 2010 72
Plasma cells.
Other haemopoietic cells.
Abnormal cells (e.g. blast cells, metastatic infiltrates).
Iron stain.
Cytochemistry.
Other investigations (e.g. cytogenetics, PCR, FISH,
microbiology).
Summary of flow cytometry findings, if available.
Conclusion.
WHO classification (if relevant).
Disease code.
Signature and date of report.
The recommended bone marrow trephine report
Name of institution.
Unique specimen identifier (laboratory accession num-
ber).
Details of patient: surname, first name(s), identifica-
tion number, age or date of birth, gender, contact
details (e.g. address, hospital location).
Name of responsible physician.
Name of  requesting doctor.
Date of procedure.
Significant clinical history including physical findings,
recent chemo/radiotherapy, cytokine therapy and per-
tinent lab results.
Indication for bone marrow examination.
Procedure performed (aspirate/trephine biopsy).
Anatomic site of  aspirate/trephine biopsy.
Aggregate length of  biopsy core.
Adequacy and macroscopic appearance of core.
Percentage and pattern of  cellularity.
Bone architecture.
Location, number, morphology and pattern of  dif-
ferentiation for erythroid, myeloid, megakaryocytic lin-
eages, lymphoid cells, plasma cells and macrophages.




Other investigations (e.g. FISH, PCR).
Conclusion.
Disease code.
Signature and date of report.
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ANSWERS
1. (A) CORRECT.
Food allergies are typically a form of  type I hy-
persensitivity reaction. The allergens react with IgE
bound to mast cells, mainly in skin and gastrointes-
tinal tract
2. (C) CORRECT.
These non-specific findings put together suggest
possible autoimmune disease. An ANA is a good
way to begin the workup, then more specific tests
can be ordered. Antigen-antibody complexes of
many autoimmune diseases can precipitate in a
variety of locations, typically trapped in basement
membranes in sites such as skin, synovium, pleura,
pericardium, and glomeruli.
3. (E) CORRECT.
Recurrent bacterial infections suggest a lack of  B-
cell immune function with lack of gamma globu-
lin production. Once maternal antibody is gone,
the disease is manifested more severely.
4. (D) CORRECT.
He has hyper-IgM syndrome, an X-linked disor-
der. The CD40-CD40L interaction is involved
with isotype switching from IgM production, thus
accounting for his lack of IgG and IgA. This ac-
counts for bacterial infections. However, some
degree of cell mediate immune defect is present
as well.
5. (D) CORRECT.
Polymyositis-dermatomyositis is present. The vio-
laceous skin rash is often quite subtle and limited
to the face.
